Indeed, early preclinical data have shown that KRAS mutations correlate with a greater sensitivity to pemetrexed in NSCLC models (30) probably due to the pemetrexed ability to alter KRAS RNA expression. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.